{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:23:18Z","timestamp":1789539798805,"version":"build-2803163510"},"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sichuan Provincial Drug Administration","award":["2024012"],"award-info":[{"award-number":["2024012"]}]},{"name":"Sichuan Provincial Health Care Committee","award":["Chuan Gan Yan 2021-226"],"award-info":[{"award-number":["Chuan Gan Yan 2021-226"]}]},{"name":"Chengdu Health Commission","award":["2022005"],"award-info":[{"award-number":["2022005"]}]},{"name":"the Committee of Drug Induced Diseases, Chinese Pharmacological Society","award":["ADR2024MS17"],"award-info":[{"award-number":["ADR2024MS17"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Fondaparinux is a widely used anticoagulant for treating venous thromboembolism and acute coronary syndrome by inhibiting factor Xa. However, it carries a risk of bleeding. This study analyzes its safety using the FDA Adverse Event Reporting System (FAERS) database to guide clinical use and future research. Data from 2004 Q1 to 2024 Q3 were examined using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) methods. Among 21,483,491 reports, 5,788 were related to fondaparinux, with 17,523 adverse events (AEs). The most affected systems were vascular (n\u2009=\u20092046) and blood\/lymphatic (n\u2009=\u20091125). Abnormal coagulation factor X concentration, thrombosis with thrombocytopenia syndrome, and incision site hematoma had the strongest signals. AEs were more frequent in females and elderly patients, especially within the first month. Additional Preferred Term (PT)\u2013level signals defined in MedDRA were observed, including heparin induced thrombocytopenia and eosinophilia. Heightened pharmacovigilance particularly in older adults may be warranted. This study enhances understanding of fondaparinux\u2019s safety, providing insights for reducing risks and ensuring safer clinical application.<\/jats:p>","DOI":"10.1371\/journal.pone.0342548","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:25:15Z","timestamp":1770834315000},"page":"e0342548","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1963-9481","authenticated-orcid":true,"given":"Fengjiao","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-505X","authenticated-orcid":true,"given":"Liuyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-9177","authenticated-orcid":true,"given":"Yuan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"9","key":"pone.0342548.ref001","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement","volume":"344","author":"Pentasaccharide Investigators","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0342548.ref002","article-title":"Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"M Valgimigli","year":"2016","journal-title":"Eur Heart J"},{"key":"pone.0342548.ref003","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g6419","article-title":"Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors","volume":"349","author":"S Bangalore","year":"2014","journal-title":"BMJ"},{"issue":"3","key":"pone.0342548.ref004","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"M Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"pone.0342548.ref005","doi-asserted-by":"crossref","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"WH Geerts","year":"2008","journal-title":"Chest"},{"issue":"1","key":"pone.0342548.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(97)00042-X","article-title":"Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide","volume":"86","author":"JM Walenga","year":"1997","journal-title":"Thromb Res"},{"issue":"7","key":"pone.0342548.ref007","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1517\/13543784.9.7.1595","article-title":"Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors","volume":"9","author":"AR Porcari","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"pone.0342548.ref008","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/s-0038-1649967","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org31540) with high affinity to antithrombin III in man","volume":"74","author":"B Boneu","year":"1995","journal-title":"Thromb Haemost"},{"issue":"22","key":"pone.0342548.ref009","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/01.CIR.102.22.2726","article-title":"Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A\/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators","volume":"102","year":"2000","journal-title":"Circulation"},{"issue":"22","key":"pone.0342548.ref010","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"SM Bates","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"pone.0342548.ref011","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"GH Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"pone.0342548.ref012","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"KA Martin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"pone.0342548.ref013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor\u2019s Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis","volume":"61","author":"SK Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"22","key":"pone.0342548.ref014","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"HJ Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"key":"pone.0342548.ref015","volume-title":"COVID-19 clinical management living guidance","year":"2025"},{"issue":"9","key":"pone.0342548.ref016","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/14740338.2016.1221395","article-title":"The safety of fondaparinux sodium for the treatment of venous thromboembolism","volume":"15","author":"D Mastroiacovo","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"pone.0342548.ref017","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jama.2014.10538","article-title":"Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis","volume":"312","author":"LA Castellucci","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"pone.0342548.ref018","article-title":"Factor Xa inhibitors for acute coronary syndromes","author":"V Brito","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"pone.0342548.ref019","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"11","key":"pone.0342548.ref020","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/pds.2014","article-title":"Selected control events and reporting odds ratio in signal detection methodology","volume":"19","author":"N Ooba","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"pone.0342548.ref021","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Y Yin","year":"2022","journal-title":"Sci Rep"},{"key":"pone.0342548.ref022","doi-asserted-by":"crossref","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Y Hu","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"pone.0342548.ref023","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"EG Brown","year":"2004","journal-title":"Drug Saf"},{"issue":"1","key":"pone.0342548.ref024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1197\/jamia.M3378","article-title":"MedEx: a medication information extraction system for clinical narratives","volume":"17","author":"H Xu","year":"2010","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"pone.0342548.ref025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0342548.ref026","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pone.0342548.ref027","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"A Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"pone.0342548.ref028","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System","volume":"53","author":"W Dumouchel","year":"1999","journal-title":"The American Statistician"},{"issue":"6","key":"pone.0342548.ref029","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"A Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0342548.ref030","volume-title":"Arixtra (fondaparinux sodium) injection: prescribing information","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"pone.0342548.ref031","unstructured":"Medicines Agency E. Arixtra. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arixtra#authorisation. 2008."},{"issue":"10","key":"pone.0342548.ref032","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012184","article-title":"Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis","volume":"8","author":"A Kumar","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"pone.0342548.ref033","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.V110.11.2148.2148","article-title":"Gender Differences in Bleeding Problems and Implications for the Assessment of a Bleeding Disorder","volume":"110","author":"M Pai","year":"2007","journal-title":"Blood"},{"issue":"2","key":"pone.0342548.ref034","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2006.06.004","article-title":"Hemostasis and aging","volume":"60","author":"M Franchini","year":"2006","journal-title":"Critical reviews in oncology\/hematology"},{"key":"pone.0342548.ref035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/CIA.S9399","article-title":"Antithrombotic therapy in very elderly patients with atrial fibrillation: is it enough to assess thromboembolic risk?","volume":"5","author":"Y Guo","year":"2010","journal-title":"Clin Interv Aging"},{"issue":"2","key":"pone.0342548.ref036","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cardiores.2004.12.027","article-title":"Endothelial aging","volume":"66","author":"RP Brandes","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"8","key":"pone.0342548.ref037","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/hh0801.089861","article-title":"Nitric oxide insufficiency, platelet activation, and arterial thrombosis","volume":"88","author":"J Loscalzo","year":"2001","journal-title":"Circ Res"},{"key":"pone.0342548.ref038","first-page":"165","article-title":"Use of anticoagulants in elderly patients: practical recommendations","volume":"4","author":"H Robert-Ebadi","year":"2009","journal-title":"Clin Interv Aging"},{"issue":"18","key":"pone.0342548.ref039","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2007.07.042","article-title":"Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial","volume":"50","author":"SR Mehta","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"pone.0342548.ref040","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"NR Bijsterveld","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"pone.0342548.ref041","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine","volume":"24","author":"JA Frontera","year":"2016","journal-title":"Neurocrit Care"},{"issue":"2","key":"pone.0342548.ref042","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-3148.2011.01125.x","article-title":"Emergency reversal of pentasaccharide anticoagulants: a systematic review of the literature","volume":"22","author":"J Elmer","year":"2012","journal-title":"Transfus Med"},{"issue":"5","key":"pone.0342548.ref043","first-page":"184","article-title":"Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid","volume":"63","author":"F Huvers","year":"2005","journal-title":"Neth J Med"},{"key":"pone.0342548.ref044","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2020.11.033","article-title":"Is chemoprophylaxis required after total knee and total hip arthroplasty in the Asian population? A systematic review and network meta-analysis","volume":"198","author":"S Xu","year":"2021","journal-title":"Thromb Res"},{"issue":"2","key":"pone.0342548.ref045","article-title":"Treatment for superficial thrombophlebitis of the leg","volume":"2","author":"M Di Nisio","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"pone.0342548.ref046","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/jog.13686","article-title":"Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high-risk women following gynecological surgery","volume":"44","author":"I Indirayani","year":"2018","journal-title":"J Obstet Gynaecol Res"},{"key":"pone.0342548.ref047","article-title":"Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021","author":"Y Wang","year":"2025","journal-title":"Clin Nephrol"},{"issue":"23","key":"pone.0342548.ref048","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.2021013839","article-title":"The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia","volume":"139","author":"A Singh","year":"2022","journal-title":"Blood"},{"key":"pone.0342548.ref049","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/978-3-031-62373-8_27","article-title":"Heparin Induced Thrombocytopenia (HIT)","volume-title":"Non Neoplastic Hematologic Disorders: A Quick Review of Modern Diagnostic and Therapeutic Approaches","author":"S Thapa","year":"2024"},{"issue":"7","key":"pone.0342548.ref050","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00590-018-2212-0","article-title":"The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty","volume":"28","author":"Y Izushi","year":"2018","journal-title":"Eur J Orthop Surg Traumatol"},{"issue":"8","key":"pone.0342548.ref051","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1021\/acs.bioconjchem.2c00316","article-title":"When Will Fondaparinux Induce Thrombocytopenia?","volume":"33","author":"L-Y Chen","year":"2022","journal-title":"Bioconjug Chem"},{"issue":"5","key":"pone.0342548.ref052","first-page":"813","article-title":"Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia","volume":"116","author":"TE Warkentin","year":"2016","journal-title":"Thromb Haemost"},{"issue":"5","key":"pone.0342548.ref053","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12179","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"91","author":"VR Bhatt","year":"2013","journal-title":"Eur J Haematol"},{"issue":"25","key":"pone.0342548.ref054","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"TE Warkentin","year":"2007","journal-title":"N Engl J Med"},{"key":"pone.0342548.ref055","doi-asserted-by":"crossref","first-page":"1165437","DOI":"10.3389\/fonc.2023.1165437","article-title":"Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study","volume":"13","author":"L Wang","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0342548.ref056","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/jth.12453","article-title":"EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs","volume":"12","author":"P Gueret","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"16","key":"pone.0342548.ref057","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"RD Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"pone.0342548.ref058","unstructured":"European Medicines Agency. Arixtra: EPAR \u2013 product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arixtra. 2024."},{"issue":"3","key":"pone.0342548.ref059","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cll.2024.04.012","article-title":"Routine Coagulation","volume":"44","author":"EJ Favaloro","year":"2024","journal-title":"Clin Lab Med"},{"issue":"1","key":"pone.0342548.ref060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/a-1675-7824","article-title":"Management of Vascular Thrombosis in Patients with Thrombocytopenia","volume":"42","author":"M Voigtlaender","year":"2022","journal-title":"Hamostaseologie"},{"issue":"1","key":"pone.0342548.ref061","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/ijd.IJD_582_17","article-title":"Drug Reaction with Eosinophilia and Systemic Symptoms: An Update and Review of Recent Literature","volume":"63","author":"A De","year":"2018","journal-title":"Indian J Dermatol"},{"issue":"6","key":"pone.0342548.ref062","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1684\/ejd.2024.4801","article-title":"DRESS (drug reaction with eosinophilia and systemic symptoms): a possible prolonged course with sequelae","volume":"34","author":"F Dezoteux","year":"2024","journal-title":"Eur J Dermatol"},{"issue":"5","key":"pone.0342548.ref063","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/1060028018819450","article-title":"A Review and Assessment of Drug-Induced Thrombocytosis","volume":"53","author":"QT Vo","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"6","key":"pone.0342548.ref064","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration","volume":"47","author":"M Fusaroli","year":"2024","journal-title":"Drug Saf"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:25:26Z","timestamp":1770834326000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342548"}},"subtitle":[],"editor":[{"given":"Ignatius","family":"Ivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342548","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}